Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. May 24, 2026; 17(5): 118265
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.118265
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.118265
Integrated Chinese and Western medicine prolong survival in colorectal cancer with liver metastasis: A retrospective cohort study
Jiang-Yu Bian, Yu-Xing Sun, Lin-Feng Wang, Tong Zhang, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
Wen-Ting He, Department of Oncology of Chinese Medicine, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, Urumqi 830000, Xinjiang Uygur Autonomous Region, China
Chuan-Bo Liu, Department of Oncology, Dongfang Hospital of Beijing University of Chinese Medicine, Beijing 100078, China
Xue-Qian Wang, Department of Oncology, Guang’anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China
Author contributions: Bian JY, Sun YX, and Wang LF contributed to the writing of the original draft, data collection and curation; Bian JY completed the formal analysis and visualization; He WT, Liu CB, and Wang XQ were responsible for resources, methodology, and supervision; Zhang T led the conceptualization and methodology, secured funding, provided resources and oversaw the study supervision. All authors have read and approved the final version of the manuscript.
Supported by the Hospital Capability Enhancement Project of Xiyuan Hospital, China Academy of Chinese Medical Sciences, No. XYZX0201-22; and National Natural Science Foundation of China, No. 82174461.
Institutional review board statement: This study has been approved by the Ethics Review Committee of the Xiyuan Hospital of the China Academy of Chinese Medical Sciences (Approval No. 2025XLA052-1).
Informed consent statement: Due to the retrospective design of the study and the use of anonymized clinical data, the requirement for informed consent was waived by the Ethics Committee. All procedures were conducted in accordance with the Declaration of Helsinki and relevant guidelines and regulations.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: No additional data are available.
Corresponding author: Tong Zhang, PhD, Associate Chief Physician, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China. ashtray7654@126.com
Received: January 4, 2026
Revised: February 12, 2026
Accepted: April 15, 2026
Published online: May 24, 2026
Processing time: 143 Days and 20.1 Hours
Revised: February 12, 2026
Accepted: April 15, 2026
Published online: May 24, 2026
Processing time: 143 Days and 20.1 Hours
Core Tip
Core Tip: The liver is the most common site of metastasis for colorectal cancer and the primary cause of death among patients with this disease. This retrospective cohort study confirms that in real-world settings, integrated Chinese and Western medicine treatment is associated with longer overall survival in patients with liver metastases from colorectal cancer. Additionally, for patients unsuitable for local treatment, integrated Chinese and Western medicine therapy has also been shown to correlate with prolonged survival.